Anthropic Bets on Life Sciences for Its IPO
Article excerpt
Highlighted: the sentence this signal was extracted from
Anthropic aims to make life sciences a driving force for its next phase of growth. The group already claims six-figure contracts in the pharmaceutical sector, is deploying a dedicated product, and is equipping itself with a laboratory, all while promoting the contribution of AI to biomedical research. This strategy is part of an IPO filing where biology takes center stage. To date, no AI-designed drug has received FDA approval. Anthropic published survey results in August indicating that 91% of its staff believe a Nobel-level discovery by AI is likely by 2030. In the same survey, 39% of American adults share this perspective for the 2030 deadline. According to Anthropic, nine of the ten largest pharmaceutical companies and eight of the ten largest health companies in the Fortune 500 have each invested at least $100,000 in the company over a recent annual period. The company also cites its collaboration with Lilly, which it describes as a $1.3 trillion-valued company with 50,000 employees who have a Claude Enterprise account. According to Anthropic, over 85% of Lilly's staff actively use the tool. This year, Anthropic established a molecular biology laboratory in the Bay Area and acquired the biotech startup Coefficient Bio for $400 million in stock in April. Additionally, the beta version of the Claude Science product appeared in June. The company is currently looking to...
Keep reading with a free account
The rest of this article, and every signal for Anthropic, is in your free account.
